Lilly launches Axiron
INDIANAPOLIS — A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.
Lilly announced the availability of Axiron (testosterone), a topical solution designed for application under the arm.
The Food and Drug Administration approved Axiron in November, making it the only testosterone replacement therapy applied to the underarm.
ProStrakan announces U.S. launch of Abstral
BEDMINSTER, N.J. — A drug used to treat pain in cancer patients now is available in the United States.
ProStrakan Group announced Monday the launch of Abstral (fentanyl) sublingual tablets. The tablets, which disintegrate rapidly and are placed under the tongue, treat breakthrough pain, common in one-half to two-thirds of people with cancer-related pain.
The drug, an opioid and controlled substance, only is available through a Food and Drug Administration-mandated REMS program. The FDA approved the drug in January.
Pfizer to sell Capsugel to KKR
PEAPACK, N.J. — Pfizer will sell its Capsugel business to Kohlberg Kravis Roberts & Co. for nearly $2.4 billion, the drug maker said Monday.
Capsugel, which develops hard capsules and drug-delivery systems, generated about $750 million in sales last year. The company will maintain its New Jersey headquarters after the sale is complete.
“This transaction is an endorsement of Capsugel’s consistent success to date and its potential for future growth with KKR, a firm with deep industry expertise and a long history of partnering with market-leading businesses to take them to the next level,” Capsugel president and general manager Guido Driesen said. “Capsugel’s employees and I are excited to work with KKR and eager to enhance the value of our business in partnership with our customers.”